2-Year Results of Paclitaxel-Eluting Balloons for Femoropopliteal Artery Disease
| Autor: | Paolo Pantaleo, Antonio Micari, Angelo Cioppa, Paolo Rubino, Chiara Grattoni, Armando Liso, Alberto Cremonesi, Alfredo Marchese, Fausto Castriota, Giancarlo Biamino, Giuseppe Vadalà |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Male
Biocompatible Time Factors Percutaneous medicine.medical_treatment Kaplan-Meier Estimate Disease Quality of life Recurrence Surveys and Questionnaires Medicine Popliteal Artery Prospective Studies Registries Percutaneous transluminal angioplasty Middle Aged Constriction Femoral Artery Treatment Outcome medicine.anatomical_structure Italy Female Stents Radiology Cardiology and Cardiovascular Medicine Vascular Access Devices Artery medicine.medical_specialty Paclitaxel Revascularization Peripheral Arterial Disease Angioplasty Humans Ankle Brachial Index Drug-eluting balloon Adverse effect Vascular Patency Aged Pathologic Peripheral artery disease business.industry Coated Materials Cardiovascular Agents Surgery Amputation Exercise Test Quality of Life business Angioplasty Balloon Constriction Pathologic Coated Materials Biocompatible Balloon |
| Zdroj: | JACC: Cardiovascular Interventions. 6:282-289 |
| ISSN: | 1936-8798 |
| DOI: | 10.1016/j.jcin.2013.01.128 |
| Popis: | Objectives This study aimed to appraise 2-year outcomes after percutaneous treatment of femoropopliteal artery disease with paclitaxel-eluting balloons. Background Percutaneous transluminal angioplasty with paclitaxel-eluting balloons for femoropopliteal artery disease has provided favorable 1-year results. Methods Consecutive patients with Rutherford class 2 to 4 disease due to femoropopliteal lesions ≤15 mm long and with 3- to 7-mm reference vessel diameter were prospectively enrolled in a multicenter registry. Endpoints of interest included primary patency, major adverse events (the composite of death, amputation, or target lesion revascularization), changes in Rutherford class, ankle-brachial index, absolute claudication distance, and quality of life after ≥24 months. Results A total of 105 patients (114 lesions) treated with paclitaxel-eluting balloons and provisional stenting were enrolled, and final procedural success was obtained in all. Follow-up after 27 ± 3 months was obtained in 98 (93.3%) patients, showing that primary patency was maintained in 71 (72.4%), and major adverse events had occurred in 17 (17.5%), with persistently significant benefits in Rutherford class, ankle-brachial index, absolute claudication distance, and quality of life (all p Conclusions PEBs are associated with favorable functional and clinical outcomes at 2 years in patients with femoropopliteal artery disease requiring percutaneous revascularization. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|